Effect of Pressure Conditions in Uterine Decellularization Using Hydrostatic Pressure on Structural Protein Preservation
Overview
Authors
Affiliations
Uterine regeneration using decellularization scaffolds provides a novel treatment for uterine factor infertility. Decellularized scaffolds require maximal removal of cellular components and minimal damage to the extracellular matrix (ECM). Among many decellularization methods, the hydrostatic pressure (HP) method stands out due to its low cytotoxicity and superior ECM preservation compared to the traditional detergent methods. Conventionally, 980 MPa was utilized in HP decellularization, including the first successful implementation of uterine decellularization previously reported by our team. However, structural protein denaturation caused by exceeding pressure led to a limited regeneration outcome in our previous research. This factor urged the study on the effects of pressure conditions in HP methods on decellularized scaffolds. The authors, therefore, fabricated a decellularized uterine scaffold at varying pressure conditions and evaluated the scaffold qualities from the perspective of cell removal and ECM preservation. The results show that by using lower decellularization pressure conditions of 250 MPa, uterine tissue can be decellularized with more preserved structural protein and mechanical properties, which is considered to be promising for decellularized uterine scaffold fabrication applications.
Standardizing decellularization protocols for optimized uterine tissue bioengineering.
Sehic E, De Miguel-Gomez L Regen Ther. 2025; 28():183-190.
PMID: 39811067 PMC: 11731971. DOI: 10.1016/j.reth.2024.12.011.
Toward human uterus tissue engineering: Uterine decellularization in a non-human primate species.
De Miguel-Gomez L, Sehic E, Thoren E, Ahlstrom J, Rabe H, Oltean M Acta Obstet Gynecol Scand. 2024; 104(3):483-493.
PMID: 39641531 PMC: 11871112. DOI: 10.1111/aogs.15030.
Fazel Anvari Yazdi A, Tahermanesh K, Ejlali M, Babaei-Ghazvini A, Acharya B, Badea I Front Bioeng Biotechnol. 2024; 12:1418034.
PMID: 39416283 PMC: 11480021. DOI: 10.3389/fbioe.2024.1418034.
Cardiac tissue engineering: an emerging approach to the treatment of heart failure.
Rayat Pisheh H, Nojabaei F, Darvishi A, Rayat Pisheh A, Sani M Front Bioeng Biotechnol. 2024; 12:1441933.
PMID: 39211011 PMC: 11357970. DOI: 10.3389/fbioe.2024.1441933.
Noro J, Vilaca-Faria H, Reis R, Pirraco R Bioact Mater. 2024; 34:494-519.
PMID: 38298755 PMC: 10827697. DOI: 10.1016/j.bioactmat.2024.01.004.